ImmuneMed, Inc.
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.immunemed.co.kr
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06306339
- Locations
- 🇳🇱
University Medical Center Urtrecht, Utrecht, GA, Netherlands
A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Standard of care
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05808335
- Locations
- 🇰🇷
Chung-Ang University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo (intravenous, single dose)Drug: hzVSF-v13 (intravenous, single dose)Drug: hzVSF-v13 (intravenous, multiple dose)Drug: hzVSF-v13 (subcutaneous, single dose)Drug: Placebo (intravenous, multiple dose)Drug: Placebo (subcutaneous, single dose)
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04817202
- Locations
- 🇦🇺
CMAX, Clinical Research Pty Ltd., Adelaide, South Australia, Australia
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04679350
- Locations
- 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Korea, Republic of
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia
- Conditions
- COVID-19
- Interventions
- Drug: Placebo (Normal saline solution)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- ImmuneMed, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04679415
- Locations
- 🇮🇩
Rumah Sakit Pusat Pertamina (include RSPP Extension Simprug), Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
🇮🇩Rumah Sakit Pasar Minggu, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
🇮🇩Rumah Sakit Umum Persahabatan, Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia
- Prev
- 1
- 2
- Next